Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

Clara Cesana, Catherine Klersy, Bruno Brando, Annamaria Nosari, Barbara Scarpati, Linda Scampini, Alfredo Molteni, Guido Nador, Luca Santoleri, Marta Formenti, Marina Valentini, Antonino Mazzone, Enrica Morra, Roberto Cairoli

Research output: Contribution to journalArticlepeer-review


We studied circulating (C)CD34+ cells by flow cytometry in 96 patients with myelodisplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34+ counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/μl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/μl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/μl cut-off of circulating CD34+ cells retains prognostic utility, especially in intermediate-risk MDS.

Original languageEnglish
Pages (from-to)1715-1723
Number of pages9
JournalLeukemia Research
Issue number11
Publication statusPublished - Nov 2008


  • Circulating CD34 cells
  • Flow cytometry
  • International Prognostic Scoring System
  • Myelodysplastic syndrome
  • Peripheral blood
  • Prognosis
  • WHO

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Prognostic value of circulating CD34+ cells in myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this